CD40 and breast carcinoma: Agonistic CD40 therapy has the potential to bridge the gap between innate and adaptive immunity by enabling robust CD8 + T cell priming and activation, potentially overcoming the immunosuppressive barriers characteristic of ER + breast cancers.